Introduction
Antithrombin III (ATIII) is a recognized treatment for patients with congenital ATIII deficiency [1] [2] [3] [4] [5] (see also the approval of this indication by the Food and Drug Administration); in contrast, the evidence supporting its use for other clinical indications is uncertain [6] [7] [8] [9] [10] .
In Italian hospitals this drug is widely used in patients admitted to intensive care units (ICUs), who are generally given ATIII for the treatment of sepsis or disseminated intravascular coagulation (DIC). The approval of ATIII by the Italian Ministry of Health was granted nearly 10 years ago (before the profound reform of the Drug Regulatory Agency made by the Italian Ministry of Health in 1993) and has remained unchanged since then. This approval of ATIII was rather generic and included 'congenital deficiency of ATIII and all clinical conditions that can cause an acquired deficiency of ATIII'.
Three small randomized studies [7] [8] [9] and one large international trial [10] assessed the effectiveness of ATIII in sepsis, but none of these trials found a significant benefit in terms of reduced morbidity or mortality. As regards congenital deficiency, the effectiveness of ATIII is fairly well documented [1] [2] [3] [4] [5] , but these patients are rare. The other clinical indications (such as acute thrombosis or thromboembolism, prevention of DIC in hepatic coma, and treatment of bleeding episodes in cirrhosis) are supported by a small series of very preliminary studies (see, for example, the Drugdex databank, CD-ROM Drugdex, volume 110; Micromedex, Englewood, Colorado, USA).
To achieve a better definition of the current use of ATIII in Italian hospitals and to generate naturalistic data (based on routine practice) about the outcome of this treatment, we undertook a multicenter observational study.
Methods

Design of the study and aims
The study was based on a multicenter observational design. From 20 May to 20 July 2001 all consecutive patients admitted to ICUs in 20 Italian hospitals and treated with ATIII were enrolled in the study. The study had the following aims: (1) surveying the use of ATIII in patients admitted to ICUs; (2) determining the outcome of patients treated with ATIII; and (3) comparing the results obtained from our observational study with those previously found in the randomized controlled trials (RCTs).
A meta-analysis was also conducted to summarize the information deriving from four RCTs [7] [8] [9] [10] that studied the effectiveness of ATIII in sepsis.
Data collection
The following information was recorded from each patient enrolled in the study: (1) demographic characteristics (age, sex, weight); (2) congenital deficiency (y/n); (3) baseline ATIII level; (4) ward of first admission in the hospital; (5) clinical indication for using ATIII (sepsis or DIC or any other clinical condition); (6) daily dose and duration of treatment with ATIII; (7) outcome of hospitalization (alive or dead); and (8) concurrent administration of antibiotics and/or heparin.
Analysis
The information collected from each patient was analyzed by standard descriptive statistics. In the subgroup of patients with sepsis, the in-hospital mortality rate observed in our study was compared with that previously reported by the four RCTs. All rates were presented together with their 95% confidence interval (CI), which was calculated by using Equations 1.26 and 1.27 of Fleiss [11] .
Results
The overall number of patients who were admitted to ICUs during the study period was 1648. Of these patients, 216 (13%) were enrolled in our study. The characteristics of these 216 patients are presented in Table 1 .
The clinical indication for using ATIII was sepsis (n = 56), DIC (n = 50), or other (n = 101). Table 1 also reports separate information for the subgroup of 56 patients treated for sepsis.
The duration of ATIII therapy did not differ at levels of statistical significance between patients treated for different clinical indications (P = 0.57 according to an analysis of variance). The daily dose of ATIII showed a difference between sepsis and other indications ( Table 1) . Table 2 reports the outcome of hospitalization according to clinical indication. With regard to the use of ATIII in patients with sepsis, Figure 1 shows the percentage mortality rate (with 95% CI) observed in our study, together with the rates found in four previous studies [7] [8] [9] [10] .
Subgroup analyses within the patient cohort of our study did not identify any relationship between mortality and patient characteristics. The administration of heparin, which Warren et al. [10] found to have some implications for outcome, did not influence mortality in our patient series: mortality was 19.6% in the 107 patients who received heparin, compared with 30.5% in the 95 patients who did not receive this drug (P = 0.10) by Fisher's exact test; mortality was 28.6% in the 28 patients with sepsis who received heparin, compared with 42.3% in the 26 patients with sepsis who did not receive this drug (P = 0.39).
Discussion
The main scientific value of our observational and prospective study lies in its naturalistic design; the population of patients that we studied was in fact drawn from the everyday practice of more than 20 hospitals and was intentionally free from specific exclusion criteria.
In interpreting our outcome data, one disadvantage is that the group treated with ATIII was not compared with any reference group observed prospectively within our research; neither did we include any retrospective control group not treated with the drug. However, historical retrospective controls would have raised profound problems of matching the retrospective data with the prospective ones. A prospective enrollment of controls not treated with ATIII was not feasible because the therapeutic policy of the ICUs involved in our study was to administer ATIII to virtually all patients with a diagnosis of sepsis or DIC.
Regardless of our statistical indexes, a 'first-look' comparison between the data on sepsis produced by the previous RCTs (including four treatment groups and four control groups) and those observed in our naturalistic study indicates a complete overlap of the various survival rates and of their respective 95% CIs. This qualitative impression (Figure 1 ) is in agreement with the meta-analysis shown in Figure 2 (see Appendix 2 for details of its methodology).
This meta-analysis gave the following results: summary odds ratio 0.98; 95% CI 0.83-1.15, P = 0.80; χ 2 for heterogeneity 1.86; 3 degrees of freedom; P = 0.60. In this meta-analysis, the large-scale trial by Warren et al. [10] outweighed the other three small RCTs in that Warren's trial included 93% of the overall cohort of the four RCTs. In the light of the above data, there seems to be no clinical benefit in administering ATIII to critical patients with sepsis; in this context, one crucial point is that the most recent large-scale trial gave very clear results and was negative. The other clinical indications reported in our patients' series were more difficult to interpret because of the nearly complete lack of previous controlled studies exploring these therapeutic issues.
There has been a lively debate in the literature on the relative merits of observational studies and RCTs in providing useful evidence of clinical effectiveness [12] [13] [14] . Although the great majority of researchers stick to the concept that RCTs are the gold standard, common sense suggests that having information both from RCTs and from observational studies is better than having information from RCTs only. In this framework, our study advances knowledge about the use of ATIII in critical patients.
Available online http://ccforum.com/content/6/5/447 n is the number of evaluable patients. Where errors are shown these are SDs. The daily doses of ATIII according to the clinical indications were as follows: sepsis (n = 47), 1988 ± 981 units/day; disseminated intravascular coagulation (n = 46), 1857 ± 967 units/day; other indications (n = 94), 1518 ± 1000 units/day. A one-way analysis of variance showed that these values were significantly different (F = 4.1; 2 and 184 degrees of freedom; P = 0.02); post-hoc tests showed that the only difference that reached significance was between sepsis and other indications (P = 0.03). Percentages, which should be read horizontally, indicate which of the three outcomes was found in the various patient subgroups. DIC, disseminated intravascular coagulation.
Key messages
• Antithrombin III (ATIII) is a recognized treatment for patients with congenital ATIII deficiency; in contrast, the evidence supporting its use for other clinical indications is uncertain
• In Italian hospitals this drug is widely used in patients admitted to intensive care units (ICUs), who are generally given ATIII for the treatment of sepsis or disseminated intravascular coagulation
• Three small randomized studies and one large international trial have assessed the effectiveness of ATIII in sepsis, but none of these trials has found a significant benefit in terms of reduced morbidity or mortality
• Our findings, based on an observational prospective study and on an updated meta-analysis of the previous randomized controlled trials, do not support the use of this drug in ICU patients without congenital deficiency Comparison of death rates between patients given ATIII and patients given placebo in the four RCTs that met the inclusion criteria of out meta-analysis. The odds ratios of the individual studies and of our meta-analysis are denoted by dots and by a diamond, respectively; each horizontal bar indicates the 95% CI for the odds ratio, and the vertical dotted line represents the identity line. From top to bottom, datasets are the trials of Warren et al. [10] , Baudo et al. [8] , Eisele et al. [9] , and Fourrier et al. [7] ; the bottom dataset is our meta-analysis. In the four RCTs, the crude death rates in the treatment group and in the control group, respectively, were as follows: Fourrier et al. [7] , 7 of 17 versus 9 of 18; Eisele et al. [9] , 5 of 20 versus 9 of 22; Baudo et al. [8] , 31 of 50 versus 33 of 48; Warren et al. [10] , 450 of 1157 versus 448 of 1157. Odds ratio ATIII better Placebo better
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Percentage mortality rate (with 95% CI) of patients with sepsis: comparison between the results of our observational study and those reported in the four RCTs previously published. Solid lines, treatment groups; broken lines, control groups; dates of publication: 1993, Fourrier et al. [7] ; early 1998, Eisele et al. [9] ; late 1998, Baudo et al. [8] ; 2001, Warren et al. [10] and our study. 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 Publication year Percent death rate (with 95%CI)
